Benzinga | Aug 6, 2020 04:19PM EDT

Capricor Therapeutics Q2 EPS $(0.23) Beats $(0.34) Estimate, Sales $49.86K May Not Compare To $210.00K Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.34) by 32.35 percent. This is a 61.02 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $49.86 thousand which missed the analyst consensus estimate of $210.00 thousand by 76.26 percent. This is a 87.85 percent decrease over sales of $410.35 thousand the same period last year.